-
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum
Meeks, J. J., van der Heijden, M. S., Powles, T., Galsky, M. D., Al-Ahmadie, H., Nishiyama, H., Drakaki, A., Vu, T. Q., Antonuzzo, L., Wiechno, P., Atduev, V., Kann, A. G., Kim, T.-H., Suárez, C., Pous, A. F., Chang, C.-H., Xin, W., Ho, S., Gula, M. & CattoVolume, J. W. F., 1 Nov 2025, In: The Journal of Urology. 214, 5, p. 556 1 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial
Powles, T. B., van der Heijden, M. S., Loriot, Y., Bedke, J., Valderrama, B. P., Iyer, G., Kikuchi, E., Hoffman-Censits, J., Vulsteke, C., Drakaki, A., Rausch, S., Arafat, W., Park, S. H., Swami, U., Li, J. R., Duran, I., Gorla, S., Homet Moreno, B., Yu, X. & Lu, Y. T. & 1 others, , Oct 2025, In: Annals of Oncology. 36, 10, p. 1212-1219 8 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
van der Heijden, M. S., Powles, T., Gupta, S., Loriot, Y., Galsky, M. D., Valderrama, B. P., Sridhar, S. S., Yu, E. Y., Iyer, G., Kikuchi, E., Castellano, D., Hoffman-Censits, J., Drakaki, A., Mar, N., Maroto Rey, J. P., Vulsteke, C., Arafat, W., Duran, I., Dawson, N. A. & Swami, U. & 5 others, , 1 Aug 2025, In: ESMO open. 10, 8, 105544.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
